Abstract
We consider the management of safety signals that arise in the context of endpoint trials. Such trials have design features which permit the detection of signals that otherwise may be missed in more traditional settings. However, the approaches that are typically employed to address them are less than satisfactory in terms of both the analytical techniques and the communication of the findings. In this paper, alternative approaches are evaluated, and recommendations are given for a comprehensive strategy that involves appropriate use of study data as well as information external to the study. It is emphasized that formulation and implementation of an effective communication plan that enables informed decision making should be an integral component of the strategy.
Keywords: Endpoint trials, competing risks, safety evaluation, cardiovascular risk
Current Drug Safety
Title: Managing Safety Signals in Large Endpoint Trials
Volume: 3 Issue: 2
Author(s): Demissie Alemayehu
Affiliation:
Keywords: Endpoint trials, competing risks, safety evaluation, cardiovascular risk
Abstract: We consider the management of safety signals that arise in the context of endpoint trials. Such trials have design features which permit the detection of signals that otherwise may be missed in more traditional settings. However, the approaches that are typically employed to address them are less than satisfactory in terms of both the analytical techniques and the communication of the findings. In this paper, alternative approaches are evaluated, and recommendations are given for a comprehensive strategy that involves appropriate use of study data as well as information external to the study. It is emphasized that formulation and implementation of an effective communication plan that enables informed decision making should be an integral component of the strategy.
Export Options
About this article
Cite this article as:
Alemayehu Demissie, Managing Safety Signals in Large Endpoint Trials, Current Drug Safety 2008; 3 (2) . https://dx.doi.org/10.2174/157488608784529206
DOI https://dx.doi.org/10.2174/157488608784529206 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chronic Inflammation and Cancer: The Role of Endothelial Dysfunction and Vascular Inflammation
Current Pharmaceutical Design Angiotensin II Type I Receptor Blocker and Endothelial Function in Humans: Role of Nitric Oxide and Oxidative Stress
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving Forward
Current Alzheimer Research Pleural Fluid Analysis for Evaluating Pleural Effusions
Current Respiratory Medicine Reviews Efficacy and Safety of Bempedoic Acid in Patients with High Cardiovascular Risk: An Update
Current Vascular Pharmacology Approaching Neurological Diseases to Reduce Mobility Limitations in Older Persons
Current Pharmaceutical Design Dendrimers as an Effective Nanocarrier in Cardiovascular Disease
Current Pharmaceutical Design Why Should Psychiatrists and Neuroscientists Worry about Paraoxonase 1?
Current Neuropharmacology Designed Multiple Ligands: Basic Research vs Clinical Outcomes
Current Medicinal Chemistry Editorial (Thematic Issue: Targeting Inflammation in Cardiovascular Disease)
Medicinal Chemistry Critical Congenital Heart Disease in Neonates: A Review Article
Current Pediatric Reviews Cell Death: Tipping the Balance of Autoimmunity and Tissue Repair
Current Pharmaceutical Design Natriuretic Peptides in Cardiovascular Diseases of Fetus, Infants and Children
Cardiovascular & Hematological Agents in Medicinal Chemistry β-Amyloid Upregulates Intracellular Clusterin but not Secretory Clusterin in Primary Cultured Neurons and APP Mice
Current Alzheimer Research Metabolic Reprogramming of Human Cells in Response to Oxidative Stress: Implications in the Pathophysiology and Therapy of Mitochondrial Diseases
Current Pharmaceutical Design Differential Action of Phytochemicals on Platelet Apoptosis: A Biological Overview
Current Medicinal Chemistry Association of Nocturnal Heart Rate with White Matter Hyperintensity Burden in Cerebral Small Vessel Disease Patients
Current Neurovascular Research Anti-Inflammatory Agents from Plants: Progress and Potential
Current Medicinal Chemistry Oral Antiplatelet Therapy for Acute Coronary Syndromes: Aspirin, P2Y12 Inhibition and Thrombin Receptor Antagonists
Current Drug Targets Migraine and Coronary Artery Disease: An Open Study on the Genetic Polymorphism of the 5, 10 Methylenetetrahydrofolate (MTHFR) and Angiotensin I-Converting Enzyme (ACE) Genes
Central Nervous System Agents in Medicinal Chemistry